D. Gonzalez

发表

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

S. Whittaker, P. Tanière, C. Harwood, 2013, The British journal of dermatology.

Angiomatoid fibrous histiocytoma: comparison of fluorescence in situ hybridization and reverse transcription polymerase chain reaction as adjunct diagnostic modalities.

C. Fisher, K. Thway, J. Swansbury, 2015, Annals of diagnostic pathology.

The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma

C. Fisher, K. Thway, J. Swansbury, 2015, Virchows Archiv.

Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis

Manjiri Deshmukh, A. Nicholson, P. Shah, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?

Robin L. Jones, I. Judson, K. Thway, 2016, Cancer biology & therapy.

Evaluation of the optimal provision of formalin-fixed, paraffin-embedded material for reverse transcription-PCR in soft-tissue tumour diagnosis

C. Fisher, K. Thway, L. Thompson, 2016, Journal of Clinical Pathology.

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

M. Salto‐Tellez, W. Newman, M. Ilyas, 2014, Journal of Clinical Pathology.

Primary Pulmonary Myxoid Sarcoma With EWSR1-CREB1 Fusion: A New Tumor Entity

A. Nicholson, C. Fisher, K. Thway, 2011, The American journal of surgical pathology.

Utility of sarcoma-specific fusion gene analysis in paraffin-embedded material for routine diagnosis at a specialist centre

C. Fisher, K. Thway, J. Swansbury, 2010, Journal of Clinical Pathology.

Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.

A. Nicholson, A. Wotherspoon, C. Nutting, 2013, Lung cancer.

A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests

F. López-Ríos, D. Gonzalez, B. Angulo, 2014, Expert review of molecular diagnostics.

Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques

Robin L. Jones, C. Fisher, K. Thway, 2017, Virchows Archiv.

The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities

Robin L. Jones, C. Fisher, I. Judson, 2017, British Journal of Cancer.

Ancillary molecular analysis in the diagnosis of soft tissue tumours: reassessment of its utility at a specialist centre

C. Fisher, K. Thway, J. Swansbury, 2015, Journal of Clinical Pathology.

Concerns regarding BRAF testing algorithm: reply from authors

S. Whittaker, P. Tanière, C. Harwood, 2013, The British journal of dermatology.

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.

A. Nicholson, S. Popat, Merina Ahmed, 2013, Lung cancer.

A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours

J. Coindre, M. Debiec‐Rychter, S. Pilotti, 2011, Journal of Gastroenterology.

Meningeal alveolar soft part sarcoma confirmed by characteristic ASPCR1‐TFE3 fusion

C. Fisher, I. Bodi, D. Gonzalez, 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

KIT and BRAF Mutational Status in a Patient with a Synchronous Lentigo Maligna Melanoma and a Gastrointestinal Stromal Tumor

P. Szlosarek, N. Dhomen, R. Marais, 2012, American Journal of Clinical Dermatology.

External quality assessment of BRAF molecular analysis in melanoma

J. Fairley, Z. Deans, B. O’Sullivan, 2013, Journal of Clinical Pathology.

ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

A. Nicholson, J. Swansbury, S. Popat, 2012, Lung cancer.